Table 1

Effect of 6-OHDA-lesion and STN-HFS on bilateral changes of optical density measurements of immunoreactive signals for VGLUT1-3
VGLUT1 VGLUT2 VGLUT3
Ipsilateral side Controlateral side Ipsilateral side Controlateral side Ipsilateral side Controlateral side
A Controls 6-OHDA Controls 6-OHDA Controls 6-OHDA Controls 6-OHDA Controls 6-OHDA Controls 6-OHDA
CPu 51,35 (±3,2) 53,33 (±1,9) 48,78 (±3,4) 52,59(±1,7) 20,15 (±2,38) 12,64*(±1,5) -37% 19,76 (±2,3) 13,38*(±0,6) -33% 16, 65(±0,8) 18,15 (±1,7) 15,37 (±0,8) 16, 33 (±3,1)
PM Cx 55,54 (±3,3) 48,3 (±2,1) 55,81 (±2,9) 48,07 (±2,8) 18,56 (±1,7) 10,93*(±0,6) -42% 18,5 (±2,1) 11,12*(±0,6) -40% 14,34 (±0,9) 13,09 (±2,4) 14,39 (±0,9) 13, 02 (±2,5)
SS Cx 45,93 (±3) 35,37 (±1,6) 45,93 (±1,6) 38,93 (±1,6) 15,79 (±1,81) 9,22*(±0,4) -42% 16,44 (±1,8) 10,57*(±0,6) -36% 12,01 (±0,6) 10,28 (±2,1) 12,89 (±0,7) 11,63 (±2,4)
Acb 54,15 (±2,8) 63,43 (±2,8) 51,52 (±3,6) 59,65 (±3,1) 22,55 (±2,7) 13,56*(±2,1) -40% 22,14 (±2,6) 13,91*(±2,1) -47% 18,84 (±0,9) 23,33 (±1,1) 19,04 (±1,1) 23 (±1,2)
Thalamus 41,18 (±3,4) 34,15 (±1,7) 41,86 (±3,3) 32,47 (±1,1) 16,83 (±2,3) 8,85*(±0,4) -48% 17,49 (±2,4) 9,05*(±0,7) -48% 11,38 (±0,5) 9,85 (±1,3) 11,43 (±0,5) 9,79 (±1,1)
STN 21,13 (±2,7) 23, 56 (±4,6) 19,25 (±2,5) 20,65 (±4,2) 16,83 (±2,1) 7,66*(±1,3) -55% 15,53 (±2,3) 9,32*(±0,5) -40% ND ND ND ND
GP ND ND ND ND 12,78 (±1,9) 7,97(±1) 13,39 (±1,7) 8,83 (±1,1) ND ND ND ND
SNr ND ND ND ND 51,1 (±2,4) 11,26*(±0,3) -25% 15,76 (±2,2) 11,39*(±0,5) -28% ND ND ND ND
Ipsilateral side Controlateral side Ipsilateral side Controlateral side Ipsilateral side Controlateral side
B 6-OHDA 6-OHDA + STN-HFS 6-OHDA 6-OHDA + STN-HFS 6-OHDA 6-OHDA + STN-HFS 6-OHDA 6-OHDA + STN-HFS 6-OHDA 6-OHDA + STN-HFS 6-OHDA 6-OHDA + STN-HFS
CPu 53,33 (±1,8) 65,07*(±3,4) +22% 52,59 (±1,7) 64,43(±3,2) +23% 12,64 (±1,5) 17,81*(±1,4) +41% 13,38 (±0,6) 17,61*(±1,8) +32% 18,15 (±1,7) 26,13*(±2,9) +44% 16,33 (±3,1) 24,88*(±1,8) +53%
PM Cx 48,3 (±2,2) 63,08*(±3,3) +31% 48,07 (±2,8) 64, 79*(±3,5) +35% 10,93 (±0,6) 16,93*(±1,6) +55% 11,12 (±0,6) 16,86*(±1,8) +52% 13,09 (±2,4) 20*(±1,9) +53% 13,02 (±2,5) 16,62*(±1,7) +51%
SS Cx 35,75 (±1) 54,25*(±3,8) +52% 38,93 (±1,6) 55,08*(±3,8) +41% 9,22 (±0,4) 14,03*(±1,4) +52% 10,57 (±0,6) 13,38*(±1,6) +27% 10,28 (±2,1) 20,44*(±2,1) +99% 11,63 (±2,4) 16,78*(±1,4) +44%
Acb 63,43 (±2,8) 65,39 (±3,9) 59,65 (±4,1) 65,06 (±4,1) 13,56 (±2,1) 20,25*(±1,3) +49% 13,91 (±2,1) 18,78*(±1,2) +35% 23,23 (±1,1) 31,7* (1,2) +36% 23 (±1,2) 31,89*(±1,2) +38%
Thalamus 34,15 (±1,7) 48,1*(±3,8) +41% 32,47(±1,1) 46,37 (±3,6) +43% 8,85 (±0,4) 14,63*(±1,6) +65% 9,05 (±0,7) 13,5*(±1,5) +449% 9,85 (±1,3) 20,3*(±1,6) +106% 9,79 (±1,1) 19,38*(±2,5) +98%
STN 23,56 (±4,6) 17,78 (±2,6) 20,65 (±4,2) 19,34 (±3) 7,66 (±1,3) 14,79*(±1,5) +93% 9,32 (±0,5) 15,94*(±1,9) +71% ND ND ND ND
GP ND ND ND ND 7.97 (±1) 10,18 (±0,9) 8,83 (±1,1) 9,61 (±1) ND ND ND ND
SNr ND ND ND ND 11,26 (±0,3) 15,84*(±1,3) +41% 11,39 (±0,5) 16,64*(±1,4) +46% ND ND ND ND

A, Modifications of VGLUT1-3 expression induced by unilateral 6-OHDA-lesion of SNc (control rats, n = 9; 6-OHDA rats, n = 6). *p<0.05, vs control group.

B, Modifications of VGLUT1-3 expression induced by unilateral STN-HFS in 6-OHDA lesioned rats (6-OHDA rats, n = 6; 6-OHDA rats + STN-HFS, n = 10). *p<0.05, vs non stimulated 6-OHDA-lesioned group. Values of optical densities measurements are expressed as a mean ± standard error (SEM). Data were analyzed for each brain structure by Kruskal-Wallis tests with SigmaStat 3.1 software. Post-hoc analyses were carried out with the Dunn’s method. Bold numbers correspond to significant differences. Ipsilateral side: related to the lesion and/or stimulation side; Controlateral side: related to the lesion and/or stimulation side; Acb, Accumbens nucleus; CPu, Caudate Putamen (striatum); GP, Globus Pallidus; PM Cx, Premotor Cortex; SNr, Substantia nigra pars reticulata; SS Cx, Somatosensory Cortex; STN, Subthalamic nucleus; Thalamus (VL/VM).

Favier et al.

Favier et al. BMC Neuroscience 2013 14:152   doi:10.1186/1471-2202-14-152

Open Data